Peptide Lab HQ Research Guide
Cartalax
A research-focused compound profile covering Cartalax identity, AED tripeptide research, cartilage and connective-tissue model context, peptide bioregulator research, concentration reference, preparation reference, and safety considerations.
Compound Data
Compound Profile
| Compound Name | Cartalax |
|---|---|
| Common Research Name | AED tripeptide |
| Common Synonyms | Ala-Glu-Asp, Alanyl-glutamyl-aspartic acid, T-31 peptide, AED peptide |
| Compound Type | Synthetic ultrashort tripeptide / peptide bioregulator research compound |
| PubChem CID | 87815447 |
| Amino Acid Length | 3 amino acids |
| Amino Acid Sequence | Ala-Glu-Asp |
| Short Sequence | AED |
| Molecular Formula | C₁₂H₁₉N₃O₈; verify against supplier COA |
| Molecular Weight | Approximately 333.29 g/mol; verify against supplier COA |
| Research Category | Peptide bioregulator, cartilage model, connective-tissue model, chondrocyte signaling, cellular renewal, extracellular matrix, and aging-marker research |
| Research Context | Commonly discussed in peptide bioregulator research involving cartilage, connective tissue, cell signaling, and tissue-specific regulatory models. |
| Appearance | White to off-white lyophilized powder, depending on supplier documentation |
| Use | For laboratory research use only. |
Research Applications
Key Research Applications
Cartalax is commonly discussed in controlled research models involving ultrashort peptide bioregulation, AED tripeptide signaling, cartilage-model context, connective-tissue response, chondrocyte-associated pathways, extracellular matrix observations, and cellular aging-marker research.
Peptide Bioregulator Research
Cartalax is commonly positioned within ultrashort peptide bioregulator research, where small peptide sequences are studied for tissue-specific signaling and gene-expression related effects.
Cartilage Model Context
Cartalax is commonly discussed in cartilage-focused research contexts involving chondrocyte signaling, cartilage matrix observations, and connective-tissue response models.
Connective-Tissue Research
Used in research discussions involving extracellular matrix balance, collagen-associated pathways, tissue maintenance, and structural tissue-response documentation.
Cellular Renewal Models
AED-related short peptide research is commonly discussed in cellular renewal, proliferation, and aging-marker research under controlled laboratory conditions.
Inflammatory-Response Context
Cartilage and connective-tissue research often tracks inflammatory markers, matrix-degradation pathways, oxidative stress, and cellular stress-response signals.
Structure & Stability Research
As a simple tripeptide, Cartalax may also be used in solubility, stability, peptide-interaction, and formulation-compatibility research.
Research Scope
These applications are provided for educational and research-reference purposes only. Cartalax research is limited compared with larger peptide categories, and outcomes may vary based on sequence identity, purity, study model, concentration, exposure duration, and laboratory conditions.
Reference Only
Reconstitution / Research Dosing Reference
Quick Reference Summary
| Reference Vial | 20 mg Cartalax |
|---|---|
| Primary Solution Volume | 1.0 mL bacteriostatic water |
| Primary Concentration | 20 mg/mL |
| Measurement Reference | On a U-100 syringe, 1 unit = 0.01 mL. |
| Amount per U-100 Unit | At 20 mg/mL, 1 unit equals 0.2 mg / 200 mcg Cartalax. |
| Storage Reference | Refrigerate at 2–8°C / 35.6–46.4°F after reconstitution, protected from direct light. |
Reconstitution Steps
- Draw 1.0 mL bacteriostatic water using a sterile syringe for the main concentration reference shown below.
- Slowly add the BAC water down the side of the vial wall.
- Gently roll or swirl the vial until the material is completely dissolved. The solution should appear clear to slightly hazy depending on concentration and supplier format. Do not shake!
- Because this is a concentrated 20 mg/mL preparation, verify complete dissolution before recording final preparation details.
- Label with compound name, vial amount, concentration, solvent volume, preparation date, storage conditions, and handling notes.
- Store refrigerated at 2–8°C / 35.6–46.4°F, protected from direct light.
Published Research Context
| Reference Type | Reported Amount / Context | Research Notes |
|---|---|---|
| Compound Identity Reference | Cartalax, commonly referenced as AED / Ala-Glu-Asp | Cartalax is commonly discussed as an ultrashort synthetic tripeptide bioregulator associated with cartilage, connective-tissue, and tissue-specific regulatory research contexts. |
| Peptide Bioregulator Research | Model-dependent concentration and endpoint tracking | Commonly discussed in short-peptide bioregulator, DNA / chromatin interaction, gene-expression, cellular-response, tissue-specific marker, and regulatory peptide research contexts. |
| Cartilage / Connective-Tissue Research | Cartilage matrix and connective-tissue model context | Cartalax-related research discussions commonly include cartilage tissue, chondrocyte-associated markers, connective-tissue integrity, extracellular-matrix markers, collagen-associated markers, and joint-model observations. |
| Fibroblast / Proliferation-Marker Research | Ki-67, p53, caspase-3, and cellular-renewal marker context | Public research discussions reference Cartalax in relation to fibroblast proliferation markers, apoptosis-associated markers, cellular-renewal markers, and tissue-maintenance research models. |
| Cellular-Aging Research Context | Senescence and tissue-resilience marker context | Cartalax is often discussed in relation to cellular-aging markers, tissue-specific aging pathways, extracellular-matrix homeostasis, stress-response markers, and regenerative-model observations. |
| Gene-Expression Research Context | Short peptide / gene-expression marker context | Short peptide bioregulator literature commonly discusses DNA interaction, regulatory sequence context, chromatin structure, and changes in gene-expression marker patterns depending on the model. |
| Public Protocol-Style Reference | Milligram-range reference examples | Public protocol-style references commonly describe Cartalax in milligram-range examples. These are not clinical dosing standards. |
| Clinical / Research-Chemical Status | No universal research-chemical protocol established | Published study references, public protocol-style references, clinical-use references, or wellness protocols should not be treated as dosing instructions for research-chemical vial formats. |
Concentration Reference
| Vial Amount | Solution Volume | Final Concentration |
|---|---|---|
| 20 mg | 1.0 mL | 20 mg/mL |
Research Dosing Amount / Volume Reference
| Reference Amount | Volume at 20 mg/mL | U-100 Unit Reference | Approx. References per 20 mg Vial |
|---|---|---|---|
| 0.5 mg / 500 mcg | 0.025 mL | 2.5 units | 40 |
| 1 mg / 1000 mcg | 0.05 mL | 5 units | 20 |
| 2 mg / 2000 mcg | 0.10 mL | 10 units | 10 |
| 5 mg / 5000 mcg | 0.25 mL | 25 units | 4 |
| 10 mg / 10000 mcg | 0.50 mL | 50 units | 2 |
| 20 mg / 20000 mcg | 1.00 mL | 100 units | 1 |
Research Frequency / Amount Reference
| Research Window | Frequency | Reference Amount | Units / Volume Reference |
|---|---|---|---|
| Lower Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 0.5 mg reference amount | 2.5 units / 0.025 mL |
| Standard Conversion Reference | Public protocol-style reference, not a clinical dosing standard | 1 mg reference amount | 5 units / 0.05 mL |
| Mid-Range Conversion Example | Calculation reference only | 2 mg reference amount | 10 units / 0.10 mL |
| Upper Conversion Example | Calculation reference only | 5 mg reference amount | 25 units / 0.25 mL |
| High Conversion Example | Calculation reference only | 10 mg reference amount | 50 units / 0.50 mL |
| Full-Vial Preparation Reference | Preparation-level calculation reference | 20 mg reference amount | 100 units / 1.00 mL |
Common Research Windows
| Reference Window | Common Length | Research Notes |
|---|---|---|
| Cell-Culture / Cartilage Marker Window | 24–72 hours | May be used for chondrocyte-associated markers, extracellular-matrix markers, collagen-associated markers, fibroblast-response markers, gene-expression, or peptide-response documentation depending on the model. |
| Acute Connective-Tissue Observation Window | Single session to several days | Used for early response tracking, cellular-marker comparison, matrix-marker observation, apoptosis-associated marker tracking, or short-term pathway documentation depending on the research design. |
| Short Research Window | 1–2 weeks | May be used for short-duration controlled observation involving cartilage matrix, connective-tissue, fibroblast response, cellular-aging markers, or gene-expression endpoints. |
| Standard Protocol-Style Window | 2–4 weeks | Commonly used in public protocol-style references for structured observation and comparison across baseline and follow-up periods. |
| Extended Observation Window | 4–8 weeks | Used when longer documentation is needed for extracellular-matrix trends, connective-tissue marker comparison, cartilage-associated marker tracking, or follow-up marker documentation. |
| Follow-Up / Washout | 1–4 weeks | Used to document post-study observations, marker return, delayed response patterns, or follow-up data depending on the research model. |
Research Note: These tables are provided for educational, research-planning, concentration, frequency-reference, and volume-reference purposes only. Cartalax, commonly referenced as AED / Ala-Glu-Asp, is discussed in peptide bioregulator, cartilage-associated, connective-tissue, extracellular-matrix, collagen-associated marker, fibroblast-response, chondrocyte-associated marker, cellular-aging, apoptosis-associated marker, gene-expression, and tissue-specific regulatory research contexts. This reference uses a 20 mg vial reconstituted with 1.0 mL bacteriostatic water, creating a 20 mg/mL concentration. Higher-concentration preparations may require supplier-specific handling, solvent-volume, or solubility notes; verify against the COA, batch record, or formula record when available. Published study references and public protocol-style frequency references are not universal research-chemical dosing standards and should not be treated as dosing instructions for research-chemical vial formats. This information is not medical advice, dosing instruction, injectable-use guidance, or a recommendation for human or animal use.
Research Notes
Research Findings & Safety Notes
Research Findings
Cartalax is commonly discussed in research involving ultrashort peptide bioregulation, AED tripeptide signaling, cartilage-model context, connective-tissue response, chondrocyte-associated pathways, extracellular matrix observations, and cellular aging-marker research.
Study Limitations
Cartalax research is limited compared with major peptide categories and includes peptide bioregulator, cell-culture, and tissue-model references. Findings should be interpreted according to peptide sequence, purity, model type, concentration, exposure duration, and endpoint selection.
Safety Considerations
Research discussion should account for peptide identity verification, sequence confirmation, sterility documentation, endotoxin risk, supplier qualification, batch records, storage conditions, and qualified laboratory handling procedures.
Use Restriction
Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease when discussed as a research-use material.
Related Supplies
Research Supplies
For research supplies, visit our affiliate partner and use code PLHQ10 to save 10% on your order.
Bacteriostatic Water
Commonly referenced in laboratory preparation workflows.
Research Syringes
Supply category for controlled laboratory research preparation.
Prep Supplies
Supporting supplies for clean handling, preparation, and documentation.
Lab Handling
Handling & Storage
Storage
Store materials according to product-specific requirements. Protect from excessive heat, moisture, and direct light.
After Reconstitution
Keep refrigerated after reconstitution unless otherwise specified by the product documentation.
Handling
Use appropriate laboratory PPE, clean handling practices, and qualified research procedures.
Documentation
Maintain batch details, COA records, preparation notes, and internal research documentation.